|
Tue, 03/04/2025 - 01:45 |
Certain Genetic Alterations May Contribute to the Primary Resistance of Colorectal and Pancreatic Cancers to KRAS G12C Inhibitors |
American Associ... |
|
Tue, 02/25/2025 - 17:51 |
Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough |
Trevi Therapeutics |
|
Fri, 07/05/2024 - 12:51 |
Viatris Brings to Completion All Previously Announced Divestitures With the Closing of its Over-the-Counter Business Divestiture |
Viatris |
|
Mon, 06/17/2024 - 12:04 |
Inhibikase Therapeutics Completes Enrollment of the Phase 2 201 Trial Evaluating Risvodetinib in Untreated Parkinsons Disease |
Inhibikase Ther... |
|
Wed, 06/05/2024 - 11:22 |
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs |
Inhibikase Ther... |
|
Wed, 05/15/2024 - 11:04 |
Novartis highlights pioneering innovation in CML with data from Scemblix Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA |
Novartis |
|
Fri, 05/10/2024 - 14:48 |
Novartis receives FDA Breakthrough Therapy designation for Scemblix in 1L CML |
Novartis |
|
Fri, 05/10/2024 - 04:58 |
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension |
Inhibikase Ther... |
|
Thu, 02/29/2024 - 03:52 |
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro |
Inhibikase Ther... |
|
Wed, 02/07/2024 - 17:48 |
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers |
Inhibikase Ther... |
|
Mon, 12/12/2022 - 12:59 |
Inhibikase Therapeutics Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro |
Inhibikase Ther... |
|
Tue, 11/15/2022 - 12:25 |
Drug shows promise in overcoming endocrine therapy resistance in breast cancer |
UTSouthwestern |
|
Tue, 08/30/2022 - 16:26 |
Novartis presents new data in breast and prostate cancer at ESMO |
Novartis |
|
Fri, 08/26/2022 - 16:15 |
Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia |
Inhibikase Ther... |
|
Tue, 08/23/2022 - 06:01 |
Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease |
Inhibikase Ther... |
|
Tue, 07/12/2022 - 08:16 |
FDA Warns Four Companies for Selling Tainted Honey-based Products with Hidden Active Drug Ingredients |
FDA |
|
Fri, 06/03/2022 - 05:23 |
New CDK4/6i data at ASCO reinforce Novartis Kisqali as only drug in class with consistently proven overall survival benefit in HR+/HER2- metastatic breast cancer |
Novartis |
|
Sun, 04/10/2022 - 16:30 |
Roswell Parks Dr. Grace Dy Presents Long-Term Data on CodeBreaK 100 Sotorasib Study |
Roswell Park Ca... |
|
Wed, 03/23/2022 - 07:45 |
Inhibikase Therapeutics to Participate in the Maxim Group 2022 Virtual Growth Conference |
Inhibikase Ther... |
|
Mon, 12/06/2021 - 11:04 |
Drug used to treat erectile dysfunction may have potential for Alzheimers |
Alzheimers Research |
|
Thu, 10/07/2021 - 12:04 |
Elacestrant May Improve Outcomes for Patients Whose Metastatic Breast Cancers Progressed on Prior Endocrine Therapy |
American Associ... |
|
Thu, 10/07/2021 - 09:40 |
Breast Cancer Patients with Estrogen Receptor Mutations May Benefit From Early Switch to Fulvestrant/Palbociclib |
American Associ... |
|
Sun, 09/19/2021 - 09:20 |
Novartis announces collaboration on HARMONIA, a Phase III, head-to-head trial evaluating Kisqali vs. Ibrance* in patients with HR+/HER2- advanced breast cancer |
Novartis |
|
Tue, 08/17/2021 - 17:42 |
New drug combo for advanced breast cancer approved for NHS in England |
Cancer Research UK |
|
Mon, 06/28/2021 - 06:18 |
Resolution Bioscience (a part of Agilent) Investigated Acquired Resistance to KRAS G12C Inhibition |
Agilent |
